A detailed history of Aton Ra Partners transactions in Moderna, Inc. stock. As of the latest transaction made, Aton Ra Partners holds 2,446 shares of MRNA stock, worth $160,824. This represents 0.48% of its overall portfolio holdings.

Number of Shares
2,446
Previous 2,717 9.97%
Holding current value
$160,824
Previous $280,000 13.21%
% of portfolio
0.48%
Previous 0.59%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$69.51 - $104.43 $18,837 - $28,300
-271 Reduced 9.97%
2,446 $243,000
Q3 2023

Oct 25, 2023

SELL
$96.41 - $126.61 $54,953 - $72,167
-570 Reduced 17.34%
2,717 $280,000
Q2 2023

Jul 18, 2023

SELL
$118.5 - $160.53 $13,983 - $18,942
-118 Reduced 3.47%
3,287 $399,000
Q1 2023

May 05, 2023

SELL
$135.66 - $197.02 $46,260 - $67,183
-341 Reduced 9.1%
3,405 $522,000
Q4 2022

Feb 02, 2023

SELL
$118.38 - $210.04 $119,918 - $212,770
-1,013 Reduced 21.29%
3,746 $672,000
Q3 2022

Nov 14, 2022

SELL
$118.07 - $194.18 $16,765 - $27,573
-142 Reduced 2.9%
4,759 $563,000
Q2 2022

Aug 15, 2022

SELL
$117.13 - $176.59 $510,101 - $769,049
-4,355 Reduced 47.05%
4,901 $700,000
Q1 2022

May 16, 2022

SELL
$126.46 - $235.05 $566,793 - $1.05 Million
-4,482 Reduced 32.62%
9,256 $1.59 Million
Q4 2021

Feb 14, 2022

BUY
$225.82 - $368.51 $15,581 - $25,427
69 Added 0.5%
13,738 $3.49 Million
Q3 2021

Nov 15, 2021

SELL
$221.9 - $484.47 $422,719 - $922,915
-1,905 Reduced 12.23%
13,669 $5.26 Million
Q2 2021

Aug 12, 2021

SELL
$129.91 - $234.98 $1.19 Million - $2.16 Million
-9,180 Reduced 37.08%
15,574 $3.66 Million
Q1 2021

May 17, 2021

BUY
$109.18 - $185.98 $239,540 - $408,040
2,194 Added 9.73%
24,754 $3.24 Million
Q4 2020

Feb 19, 2021

BUY
$65.74 - $169.86 $1.48 Million - $3.83 Million
22,560 New
22,560 $2.36 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $25.7B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.